Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
A novel device for trigeminal nerve stimulation (TNS) effectively improves attention deficit hyperactivity disorder (ADHD) symptoms in children aged 8–12 years, providing a safe nonmedication approach to treating ADHD, a recent study shows.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Preschoolers are likely to follow an unhealthy dietary pattern, and patterns high in processed food and snacks contribute to an increased risk of attention-deficit/hyperactivity disorder (ADHD), whereas a pattern high in vegetables exerts a protective effect, according to a study from China.
Individuals with attention-deficit hyperactivity disorder (ADHD) who are treated with atomoxetine or methylphenidate may have a risk for elevated heart rate and systolic blood pressure (BP), according to a meta-analysis.
Individuals with attention deficiency hyperactivity disorder (ADHD) or anxiety are at greater risk of developing bipolar disorder, according to a study. Moreover, the risk further increases in those who have received diagnoses of both ADHD and anxiety.
A substantial number of patients with gambling addiction screen positive for attention-deficit/hyperactivity disorder (ADHD), according to a Singapore study. Furthermore, these patients have lower levels of gambling-related cognitions, suggesting that their gambling behaviour is rather guided by impulsivity.
Youths treated with a 12-week course of either olanzapine, risperidone, or aripiprazole may have an increased risk for elevated adiposity and decreased insulin sensitivity, according to a recent study.
Atrial fibrillation (AF) carries an excess risk of stroke recurrence independent of comorbidity with and heart failure (HF), while HF without AF also poses a significant risk of recurrence, a study has shown.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.